Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.4069
-0.0467 (-10.30%)
Nov 16, 2026, 4:00 PM EST - Market closed

Kairos Pharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
3.134.491.270.090.440.07
Cash & Short-Term Investments
3.134.491.270.090.440.07
Cash Growth
-43.95%253.07%1267.74%-78.72%498.63%410.20%
Prepaid Expenses
0.030.050.040.01--
Other Current Assets
0.20.852.86---
Total Current Assets
3.355.394.170.10.440.07
Other Intangible Assets
-0.060.220.380.540.7
Long-Term Deferred Charges
1.021.091.380.480.06-
Total Assets
4.376.545.770.971.040.78

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
0.50.20.992.41.631.55
Short-Term Debt
---000.39
Total Current Liabilities
0.50.20.992.411.631.94
Long-Term Debt
---0.640.58-
Total Liabilities
0.50.20.993.042.221.94

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
00.020.010.010.010.1
Additional Paid-In Capital
23.1620.5813.584.123.212.08
Retained Earnings
-19.29-14.26-8.82-6.21-4.4-3.35
Shareholders' Equity
3.886.344.78-2.08-1.18-1.17
Total Liabilities & Equity
4.376.545.770.971.040.78

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
---0.640.590.39
Net Cash (Debt)
3.134.491.27-0.55-0.15-0.32
Net Cash Growth
-43.95%253.07%----
Net Cash Per Share
1.011.710.78-0.37-0.10-0.25
Filing Date Shares Outstanding
4.693.062.381.511.481.73
Total Common Shares Outstanding
3.732.971.961.511.481.73
Working Capital
2.865.193.18-2.3-1.2-1.87
Book Value Per Share
1.042.132.43-1.38-0.80-0.68
Tangible Book Value
3.886.284.55-2.46-1.72-1.87
Tangible Book Value Per Share
1.042.112.32-1.63-1.17-1.08
SEC Filings: 10-K · 10-Q